Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Abnormal Proliferation02:23

Abnormal Proliferation

5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing the 2026 Early Career Board of <i>ACS Medicinal Chemistry Letters</i>.

ACS medicinal chemistry letters·2026
Same author

Harnessing FBXO31 with Terminal Amide-Functionalized Molecules for Targeted Protein Degradation.

Journal of the American Chemical Society·2026
Same author

Covalent Reprogramming of Kinase Binders to Modulate Protein Abundance.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS.

Nature communications·2026
Same author

Harnessing FBXO31 with terminal amide-functionalized molecules for targeted protein degradation.

bioRxiv : the preprint server for biology·2026
Same author

Emerging biologic modalities for targeted protein degradation.

The Journal of biological chemistry·2026

Related Experiment Video

Updated: Jan 15, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K

Systematic Characterization of Cancer-Associated SPOP Mutants Reveals Novel and Reprogrammable Degradative

Alana G Caldwell1, Harshil Parmar2, Xiaokang Jin2

  • 1Interdisciplinary Biological Sciences Graduate Program, Northwestern University, Evanston, USA.

Chembiochem : a European Journal of Chemical Biology
|January 14, 2026
PubMed
Summary

Speckle-type POZ protein (SPOP) mutations in prostate cancer show varied effects on protein degradation. These findings reveal potential therapeutic applications for mutant-selective E3 ligases.

Keywords:
E3 ligaseprotein–protein interactionsproteomicsrecurrent mutationtargeted protein degradation

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K
Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

5.4K

Related Experiment Videos

Last Updated: Jan 15, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K
Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

5.4K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Speckle-type POZ protein (SPOP) is a key adaptor for the Cullin3-RING ligase complex.
  • SPOP mutations are common in various cancers, including prostate cancer, affecting its function.
  • The biochemical impact of specific SPOP mutations (F102C, F133L) in prostate cancer is not fully understood.

Purpose of the Study:

  • To investigate the biochemical consequences of SPOP mutations F102C and F133L.
  • To determine the substrate-binding and degradation activities of these SPOP mutants.
  • To explore the therapeutic potential of SPOP mutants.

Main Methods:

  • Quantitative proteomics was employed to analyze SPOP mutant functions.
  • Degradative activity towards nuclear basket proteins (NUP153, TPR) was assessed.
  • Cellular systems were engineered to test targeted protein degradation by SPOP mutants.

Main Results:

  • SPOP-F133L retains degradative activity towards NUP153 and TPR, unlike SPOP-F102C, indicating substrate-dependent loss-of-function.
  • SPOP-F133L partially down-regulates p53 via a Cullin-RING ligase-dependent mechanism, suggesting a new substrate.
  • Both SPOP-F102C and SPOP-F133L demonstrated the ability to support targeted protein degradation in engineered cells.

Conclusions:

  • The study elucidates the distinct degradative capacities of SPOP mutants F102C and F133L.
  • Findings suggest that SPOP mutants can be repurposed as mutant-selective E3 ligases for therapeutic strategies.
  • Understanding SPOP mutant function provides insights into cancer biology and potential therapeutic interventions.